公开(公告)号：US20230092431A1

公开(公告)日：2023-03-23

申请号：US17792030

申请日：2021-01-14

申请人： Synlogic Operating Company, Inc.

发明人： Vincent M. Isabella ,  David Lubkowicz ,  Michael James

IPC分类号： A61K35/74 ,  C12N9/00 ,  C12N9/88 ,  C12N9/10 ,  C12N15/70 ,  A61K31/4439 ,  A61P13/12 ,  A61P3/00

摘要： The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.

公开(公告)号：US20230090705A1

公开(公告)日：2023-03-23

申请号：US17798586

申请日：2021-02-12

申请人： Synlogic Operating Company, Inc.

发明人： Vincent M. Isabella ,  Sean Cotton

IPC分类号： A61K35/741 ,  C12N9/88 ,  A61P3/00

摘要： The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells that comprise an amino acid catabolism enzyme, e.g., a methionine catabolism enzyme for the treatment of diseases and disorders associated with amino acid metabolism, including homocystinuria, in a subject. The disclosure further provides pharmaceutical compositions and methods of treating disorders associated with amino acid metabolism, such as homocystinuria.

公开(公告)号：US11273184B2

公开(公告)日：2022-03-15

申请号：US15755836

申请日：2016-08-31

申请人： Synlogic Operating Company, Inc.

发明人： Vincent Isabella ,  Dean Falb ,  Cami Leigh Anderson ,  Paul Miller ,  Yves Millet ,  Jonathan Kotula

IPC分类号： A61K35/74 ,  C07K14/195 ,  C12N1/00 ,  A61P3/00 ,  C12N15/52 ,  C12N15/70

摘要： The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.

公开(公告)号：US20210369836A1

公开(公告)日：2021-12-02

申请号：US17330563

申请日：2021-05-26

申请人： Synlogic Operating Company, Inc.

发明人： Ning Li

IPC分类号： A61K39/215 ,  A61K39/00 ,  C07K16/00 ,  C07K14/71 ,  C07K14/005

摘要： Recombinant microorganisms, pharmaceutical compositions thereof, and methods of protein display on the cell surface of the microorganisms are disclosed.

公开(公告)号：US20210169942A1

公开(公告)日：2021-06-10

申请号：US17124661

申请日：2020-12-17

申请人： Synlogic Operating Company, Inc.

发明人： Dean Falb ,  Paul F. Miller ,  Jonathan W. Kotula ,  Vincent M. Isabella ,  Suman Machinani ,  Adam B. Fisher ,  Yves Millet

IPC分类号： A61K35/74 ,  A61K39/02 ,  C12N9/88 ,  C12N9/06 ,  C12N15/70 ,  C07K14/245 ,  A61K35/741 ,  C07K14/195

摘要： Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.

公开(公告)号：US20210095297A1

公开(公告)日：2021-04-01

申请号：US16864492

申请日：2020-05-01

申请人： Synlogic Operating Company, Inc.

发明人： Dean Falb ,  Vincent M. Isabella ,  Jonathan W. Kotula ,  Paul F. Miller

IPC分类号： C12N15/70 ,  C12N9/02 ,  C12N9/12 ,  A61K35/741 ,  A61K38/20 ,  A61K38/26 ,  A61K38/44 ,  A61K31/19 ,  A61K31/198

摘要： Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.